证券记录 · 已归档季度
AMGN
Amgen Inc. · Healthcare · Drug Manufacturers - General
20被追踪持有人
n/aΔ持有人
39.58M持有股份
$12.36B报告持仓市值
+0新建仓位
−0清仓
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q2 2024
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 1.52M | $603.13M | n/a | −1 |
| Q2 2026 | 169 | -1 | 364.70M | $131.99B | +5 | −7 |
| Q1 2026 | 174 | -2 | 366.40M | $128.82B | +4 | −7 |
| Q4 2025 | 175 | 0 | 394.29M | $128.98B | +2 | −1 |
| Q3 2025 | 26 | 0 | 206.42M | $58.23B | n/a | −1 |
| Q2 2025 | 24 | +1 | 183.25M | $51.15B | +2 | −1 |
| Q1 2025 | 20 | -2 | 81.79M | $25.47B | n/a | −2 |
| Q4 2024 | 22 | +2 | 74.78M | $19.48B | +2 | n/a |
| Q3 2024 | 19 | -1 | 39.65M | $12.76B | +1 | −2 |
| Q2 2024 | 20 | n/a | 39.58M | $12.36B | n/a | n/a |
持有人 · Q2 2024
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | PRIMECAP Management ✦ | 14.45M | n/a | $4.51B | 3.3% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (被动) | 12.02M | n/a | $3.75B | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (被动) | 5.81M | n/a | $1.81B | 0.3% | n/c | 1 | SEC ↗ |
| 4 | T. Rowe Price ✦ | 4.52M | n/a | $1.41B | 0.2% | n/c | 1 | SEC ↗ ×2 |
| 5 | Marshall Wace ✦ | 656.50K | n/a | $205.12M | 0.3% | n/c | 1 | SEC ↗ ×2 |
| 6 | Adage Capital Partners ✦ | 578.30K | n/a | $180.69M | 0.3% | n/c | 1 | SEC ↗ |
| 7 | Two Sigma Investments ✦ | 542.15K | n/a | $169.39M | 0.4% | n/c | 1 | SEC ↗ |
| 8 | D. E. Shaw & Co. ✦ | 306.68K | n/a | $95.82M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 9 | Wellington Management ✦ | 234.41K | n/a | $73.24M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 10 | Fisher Asset Management ✦ | 84.38K | n/a | $26.36M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | ARK Investment Management ✦ | 74.82K | n/a | $23.38M | 0.2% | n/c | 1 | SEC ↗ |
| 12 | AQR Capital Management ✦ | 73.12K | n/a | $22.85M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 13 | Millennium Management ✦ | 67.21K | n/a | $21.00M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | Renaissance Technologies ✦ | 52.24K | n/a | $16.32M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 37.27K | n/a | $11.65M | 0.0% | n/c | 1 | SEC ↗ |
| 16 | Citadel Advisors ✦ | 22.81K | n/a | $7.13M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Gotham Asset Management ✦ | 22.14K | n/a | $6.92M | 0.1% | n/c | 1 | SEC ↗ |
| 18 | Dodge & Cox ✦ | 14.38K | n/a | $4.49M | 0.0% | n/c | 1 | SEC ↗ |
| 19 | Bridgewater Associates ✦ | 8.73K | n/a | $2.73M | 0.0% | n/c | 1 | SEC ↗ |
| 20 | GAMCO Investors ✦ | 5.59K | n/a | $1.75M | 0.0% | n/c | 1 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| 本季度无新增被追踪买入方。 |
已清仓
| 本季度无被追踪的退出仓位。 |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 3,100 持有人, 420.54M 股份, $144.29B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
公开市场买入 (P)
在我们的覆盖窗口内无内部人士公开市场买入记录。
公开市场卖出 (S)
Aug 13
Khosla Rachna
Officer · 1.25K 股 · $521,365
Aug 11
Khosla Rachna
Officer · 2.00K 股 · $825,134
授予、行权及税务代扣代缴在本平台均不计入买入或卖出。 方法论
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q2 2024 ·
方法论 ·
通过API获取此数据